The Effect of Dapagliflozin on Myocardial Strain in Patients With Acute Heart Failure

Sponsor
Qilu Hospital of Shandong University
Study ID
NCT07403955
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Congestive Heart Failure Acute

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin 10mg Tab — DRUG
    Compared with the control group, dapagliflozin is started within the first month after the onset of acute heart failure.

Study Details

The goal of this clinical trial is to assess the impact of dapagliflozin on myocardial strain in patients with acute heart failure using speckle tracking echocardiography (STE). The main questions it aims to answer are: * Does dapagliflozin improve left ventricular remodeling as well as cardiac systolic and diastolic function? * Can STE more accurately assess the impact of dapagliflozin on myocardial strain in patients with acute heart failure? Researchers will compare patients receiving oral dapagliflozin to those not receiving it to see if dapagliflozin works to improve left ventricular remodeling as well as cardiac systolic and diastolic function. Participants will: * Take dapagliflozin or not every day for 1 month * Take dapagliflozin for the next 2 months * Visit the clinic at Month 1 and Month 3 for checkups and tests

Key Dates

Start date
Feb 28, 2026
Status verified
Feb 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
188 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: intervention group
    Standard treatment combined with dapagliflozin tablet 10mg qd for 3 months
  • No Intervention: control group
    Dapagliflozin tablet 10mg qd was added for two months after one month of standard treatment

Primary Outcome Measure

left ventricular global longitudinal strain (LVGLS) [ Time Frame: at 3 months ]